Services
recombinant exosomes
We have developed a platform technology to engineer the CD81 extracellular loop domain on EVs to select binders to specific cell surface proteins. Proof of Principle has been successfully achieved for recombinant extracellular vesicles targeting laminin and EGFR specifically. This technology will allow the development of a broad range of new therapeutic applications and targeting strategies in the extracellular vesicle space.
General information
EV platform technology to select specific binders: in cooperation with BOKU (University of Natural Resources and Life Sciences Vienna) and ACIB (Austrian Center of Industrial Biotechnolgy), Evercyte has generated a technology platform for the development of cell/tissue targeting extracellualr vesicles. This platform is based on the generation of a surface display library by randomization of an extracellular loop of EV surface proteins.
Recent example – generation of tumor-targeting EVs
In order to improve tumor targeting, Evercyte and MDimune have entered a collaboration where Evercyte’s novel and proprietary technology platform will be combined with MDimune´s highly expandable BioDrone® platform for the generation of targeted extracellular vesicles (EVs). Thereby identified high-affinity binders to specific tumor antigens will be used to develop novel drug-targeting vehicles.
Recent example - targeting laminin
Recombinant extracellular vesicles targeting laminin as proof-of-principle enhances cellular uptake of EVs significantly. Please have a look at our new publication "An engineered CD81-based combinatorial library for selecting recombinant binders to cell surface proteins: Laminin binding CD81 enhances cellular uptake of extracellular vesicles." J Extracell Vesicles. 2021;10:e12139.
https://pubmed.ncbi.nlm.nih.gov/34514736/
This work was performed in cooperation with ACIB, University of Natural Resources and Life Sciences, Vienna and the Ludwig Boltzmann Institute for Traumatology – the research center in collaboration with AUVA (LBI Trauma).
Leaflets - extracellular vesicles
Selected publications
(2021). An engineered CD81-based combinatorial library for selecting recombinant binders to cell surface proteins: Laminin binding CD81 enhances cellular uptake of extracellular vesicles. J Am Soc Nephrol. 2011 Jul;22(7):1221-8. https://pubmed.ncbi.nlm.nih.gov/33717998/
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
"Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed."
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
